Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Adlai Nortye Ltd

ANL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$13.25

▲ +3.03%

Market Cap $1.04B · Vol 29.39K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.04B

Small Cap

Div Yield

N/A

EPS Growth

+16.22%

YoY

RSI (14)

63.68

Momentum

Beta

N/A

vs Market

52W High

$17.20

22.97% below

52W Low

$0.90

1,372.22% above

Volume

29.39K

Avg 49.96K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

99.54%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Adlai Nortye Ltd (ANL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ANL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.23%

+44.02%

-4.40%

+39.33%

YTD

+833.10%

+644.38%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$5.00M
Net Income	$-35,528,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-713.96%
Net Profit Margin	-710.56%
ROE	N/A
ROA · ROIC	-67.22% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	9.08
P/B	N/A
P/FCF	N/A
EPS Growth	+16.22%
Outstanding Shares	235.57M

Technical Indicators

50-Day SMA	$11.46
200-Day SMA	$8.05
RSI (14)	63.68
Beta	N/A
52-Week High	$17.20
52-Week Low	$0.90

Volume Today	29.39K
Avg Daily Volume (30D)	49.96K
Relative Volume	0.59x
Volatility (10D)	39.77
Volatility (30D)	85.05
Free Float	99.54%

Analyst Consensus

BUY

Current Price $13.25

Mean Target $28.60

52W Low$0.90 52W High$17.20

Current

Target

$0.90 $17.20

Current Analyst target

+115.85% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01HP11TP9

ISINUS00704R1095

CountryCayman Islands

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Adlai Nortye Ltd. is a global clinical-stage biotechnology company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor and AN4035, a Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5).